A comparison between nebulized furosemide and salbuthamol on dyspnea improvment in chronic obstructive pulmonary disease patients reffered to shahid beheshti hospital
This study desined to evaluate the effect of nebulized furosemide on dyspnea in chronic obstructive pulmonary disease. Inclusion criteria are patients with chronic obstructive pulmonary disease who had 40 year old or more. Exclusion criteria are advanced heart disease and lung fibrosis.90 patients with chronic obstructive pulmonary disease has been studied. These patients fall into two group of patients who receive salbuthamol and furosemide as nebulizer. One group receives 40 mg of furosemide as nebulizer for 7 minutes that the time needed for its nebulization. Other group receives 5 mg of salbuthamol as nebulizer for 5 minutes that the time is needed forb its nebulization.Both of them perform in one day. Dyspnea is assessed after each nebulization as primary end point.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT201707126187N5
Registration date:2017-08-25, 1396/06/03
Registration timing:retrospective
Last update:
Update count:0
Registration date
2017-08-25, 1396/06/03
Registrant information
Name
Mohammadi Saba
Name of organization / entity
Kashan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 36 1555 0021
Email address
saba-ma@kaums.ac.ir
Recruitment status
Recruitment complete
Funding source
Kashan University of Medical Sciences
Expected recruitment start date
2014-02-20, 1392/12/01
Expected recruitment end date
2015-02-20, 1393/12/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
A comparison between nebulized furosemide and salbuthamol on dyspnea improvment in chronic obstructive pulmonary disease patients reffered to shahid beheshti hospital
Public title
The effect of nebulized furosemide and salbuthamol on dyspnea in chronic obstructive pulmonary disease
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: Patients with chronic obstructive pulmonary disease based on their spirometry who had dyspnea according to class 3-5 mmrc
Exclusion criteria: Advanced heart failure; Severe osteoarthritis; Inability to walking;Tracheal stenosis
Age
From 40 years old to 80 years old
Gender
Both
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size:
90
Randomization (investigator's opinion)
Not randomized
Randomization description
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Kashan University of Medical Sciences Research Council